Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BDP9066 is an inhibitor of Cdc42-binding kinase α (MRCKα) and MRCKβ (Kis = 0.0136 and 0.0233 nM, respectively).1 It is selective for MRCKα and MRCKβ over Rho-associated kinase 1 (ROCK1) and ROCK2 (Kis = 18.4 and 5.38 nM, respectively) and a panel of 115 additional kinases at 1 µM. BDP9066 has antiproliferative activity against a panel of 757 cancer cell lines (EC50s = <10 µM). It inhibits the phosphorylation of myosin light-chain 2 (MLC2) in SCC-12 squamous cell carcinoma cells (EC50 = 64 nM) and inhibits the motility of the same cells. BDP9066 (25 µg/animal) decreases average papilloma volume in a mouse two-stage model of skin carcinogenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA; Item No. 30383) and promoted by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014).
WARNING This product is not for human or veterinary use.
1. Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer. Cancer Res. 78(8), 2096-2114 (2018).